In that PPARγ agonists inhibit the IL-6-regulated Stat3 signaling cascade, a role for PPARγ agonists in regulating expression of miRNAs critical to the pathogenesis of hematological malignancies may be an important avenue of future scientific investigations. Here, PPARG is linked to hematologic disorder.